Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxylanthanum carbonate - Unicycive Therapeutics

Next Previous
X
Search
Drug Profile

Oxylanthanum carbonate - Unicycive Therapeutics

Alternative Names: Lanthanum dioxycarbonate; OLC; RENALAN™; RenaZorb; RZB-014; SPI-014 - Assertio Therapeutics

Latest Information Update: 03 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Altair Nanotechnologies
  • Developer Assertio Therapeutics
  • Class Hyperphosphataemia therapies; Lanthanoid series elements; Small molecules
  • Mechanism of Action Phosphate binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hyperphosphataemia

Most Recent Events

  • 03 Jun 2024 Unicycive Therapeutics anticpates FDA approval in Hyperphosphatemia by the middle of 2025
  • 03 Jun 2024 Unicycive Therapeutics plans to submit NDA to the US FDA for Hyperphosphatemia in the middle of 2024
  • 31 May 2024 Unicycive Therapeutics has patent protection for oxylanthanum carbonate in US, Canada, Europe, Japan, China, Australia, and other countries

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top